-+ 0.00%
-+ 0.00%
-+ 0.00%

InnoCare Pharma Q1 net profit jumps to RMB 102.4 million; revenue rises 38.7% to RMB 528.6 million

PUBT·04/23/2026 10:59:42
Listen to the news
InnoCare Pharma Q1 net profit jumps to RMB 102.4 million; revenue rises 38.7% to RMB 528.6 million
  • InnoCare Pharma posted Q1 2026 net profit of RMB 102.4 million, up 607.7% year over year.
  • Revenue climbed 38.7% to RMB 528.6 million, driven by higher orelabrutinib volume, new contributions from tafasitamab and zurletrectinib, plus milestone payments from Zenas BioPharma.
  • Operating profit jumped more than fivefold to RMB 104.5 million.
  • R&D spending rose 10.4% to RMB 229.2 million, while cash and related account balances totaled about RMB 7.9 billion as of March 31.
  • Management said it will continue accelerating pipeline development, aiming to sustain high-quality growth.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260423-12118941), on April 23, 2026, and is solely responsible for the information contained therein.